Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04303039 | Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects | PHASE1 | COMPLETED | 12 | — | — | May 22, 2020 | Jun 19, 2020 | Jun 23, 2020 | 1 | United States |
At times 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hrs.
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | Single 1.0 mg dose of ABP-671 in the fasted state. |
| Treatment B | EXPERIMENTAL | Single 1.0 mg dose of ABP-671 in the fed state, after a standardized breakfast. |
| Name | Type | Description |
|---|---|---|
| ABP-671 | DRUG | ABP-671 Tablet 1.0 mg |
Inclusion Criteria: * Male or female aged 18 to 60 years, inclusive * Healthy * Subjects must have the serum uric acid level at screening ≥ 3.7 mg/dL to ≤ 7.0 mg/dL for males, and ≥ 2.3 mg/dL to ≤ 6.0 mg/dL for females. * Subjects must have a Body Mass Index (BMI) between 18 and 35 kg/m2 at screeni...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amgen Inc. | AMGN | 1 | PHASE3 | Pegloticase, Methotrexate |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE1 | NNC4004-0002 |
| Protalix | PLX | 1 | PHASE2 | PRX-115, Methotrexate |
| TJ Biopharma Co., Ltd. | IMAB | 1 | PHASE2 | Plonmarlimab, Compound betamethasone |